Shionogi launches ZURZUVAE (zuranolone) 30 mg capsules in Japan for major depressive disorder, introducing a novel oral antidepressant designed to provide rapid symptom improvement through GABA-A receptor modulation.
Written By: Marka Sheshi, PharmD
Reviewed By: Pharmacally Editorial Team
Shionogi & Co., Ltd. has launched ZURZUVAE (zuranolone) 30 mg capsules in Japan for the treatment of Major Depressive Disorder (MDD), introducing a novel oral antidepressant designed to provide rapid relief from depressive symptoms.
ZURZUVAE represents a new class of antidepressant therapy with a mechanism distinct from conventional treatments. The drug functions as a positive allosteric modulator of GABA receptors at both synaptic and extrasynaptic sites, helping regulate inhibitory neurotransmission in the brain that is often disrupted in depressive disorders.
The Japanese launch is supported by results from a Phase III randomized, placebo-controlled clinical trial conducted in adults with major depressive disorder. In the study, patients received oral ZURZUVAE at a dose of 30 mg once daily for 14 consecutive days. Treatment resulted in rapid improvement in depressive symptoms compared with placebo, while safety findings showed no concerns associated with repeat administration.
Depression remains a significant public health challenge in Japan, affecting an estimated five million people. The condition is associated with substantial personal, social, and economic burden. Existing antidepressant therapies often require several weeks before meaningful symptom improvement is observed, highlighting the need for treatments that act more quickly during acute depressive episodes.
By providing a short-course oral therapy with rapid onset of action, ZURZUVAE may help address this unmet clinical need and offer a new option for patients requiring timely intervention.
The launch also aligns with Shionogi & Co., Ltd.’s broader strategy to develop healthcare solutions targeting diseases that significantly impact quality of life. The company has identified several areas of focus, including sleep disorders, hearing loss, rare pediatric diseases, and immunology and allergy conditions, as part of its effort to contribute to healthier and more fulfilling lives through innovative therapies.
References
ZURZUVAE® Capsules 30 mg for the Treatment of Major Depressive Disorder launched in Japan, 19 March 2026, https://www.shionogi.com/global/en/news/2026/03/20260319.html
About the Writer
Marka Sheshi | Doctor of Pharmacy
Driven by a deep commitment to clinical excellence, research integrity, and impactful medical writing. With a strong foundation in pharmacotherapy and patient safety, specializes in transforming complex scientific evidence into authoritative, publication-ready content. Passionate about advancing healthcare through precise, evidence-based communication that informs practice, strengthens research visibility, and improves patient outcomes.